Mossler Mark has filed 6 insider transactions across 1 company since February 2024.
Most recent transaction: a grant/award of 56980 shares of C4 Therapeutics, Inc. ($CCCC) on February 13, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Mossler Mark | Chief Accounting Officer | A | Common Stock | 56980 | $0.00 | 75,184.0000 | 96,914,418 | 313.01% | 0.06% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Mossler Mark | Chief Accounting Officer | M | Common Stock | 9420 | $0.00 | 75,184.0000 | 96,914,418 | 14.32% | 0.01% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Mossler Mark | Chief Accounting Officer | F | Common Stock | 3268 | $1.89 | 71,916.0000 | 96,914,418 | 4.35% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Mossler Mark | Chief Accounting Officer | F | Common Stock | 1586 | $3.18 | 18,204.0000 | 0 | 8.01% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Mossler Mark | Chief Accounting Officer | A | Common Stock | 18290 | $0.00 | 19,790.0000 | 0 | 1219.33% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Mossler Mark | Chief Accounting Officer | A | Stock Option (Right to Buy) | 27430 | $0.00 | 27,430.0000 | 0 | 9999.99% | 0.00% |